Improved event-related potential signs of selective attention after the administration of the cholecystokinin analog ceruletide in healthy persons.
Cholecystokinin (CCK) is co-localized with dopamine (DA) in neurons of the mesolimbic-frontocortical dopamine (DA) system, considered essential for the pathology of psychotic behavior and associated attention deficits. The present experiments in 13 healthy men aimed at examining the effects of the CCK analog ceruletide on attention as reflected by event-related brain potentials (ERPs). Subjects were tested according to a double-blind cross-over design on three occasions, following intravenous infusion of placebo, 0.5 microgram ceruletide, and 2.5 micrograms ceruletide. ERPs were recorded during the subject's performance on an auditory selective attention task including the concurrent presentation of frequent standard tones and infrequent deviant tones which the subject had to listen to, or to ignore. The processing negativity (PN) over frontocentral cortical areas, reflecting selective attention, was higher after ceruletide than placebo, this increase being most pronounced after the 2.5 micrograms dose (placebo -1.29 +/- 0.38 microV versus ceruletide -3.02 +/- 0.65 microV, p < .05). ERP signs of a general increase in cortical arousal after ceruletide did not reach significance. Likewise, mismatch negativity, an indicator of preattentive processing of stimulus deviance, was not significantly affected by the peptide. The results indicate that ceruletide affects human brain function primarily by improving selective attention.
Schreiber
H
H
Department of Neurology, University of Ulm, Germany.
Stolz-Born
G
G
Pietrowsky
R
R
Kornhuber
H H
HH
Fehm
H L
HL
Born
J
J
D000328:Adult; D001143:Arousal / Q000187:drug effects* / Q000502:physiology; D001288:Attention / Q000187:drug effects* / Q000502:physiology; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology; D001921:Brain / Q000187:drug effects / Q000502:physiology; D002108:Ceruletide / Q000494:pharmacology*; D002766:Cholecystokinin / Q000031:analogs & derivatives* / Q000502:physiology*; D003265:Contingent Negative Variation / Q000187:drug effects / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004569:Electroencephalography / Q000187:drug effects*; D005072:Evoked Potentials, Auditory / Q000187:drug effects* / Q000502:physiology; D013006:Growth Hormone / Q000097:blood; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D007262:Infusions, Intravenous; D008297:Male; D010897:Pitch Discrimination / Q000187:drug effects / Q000502:physiology
D002108:Ceruletide; D013006:Growth Hormone; D002766:Cholecystokinin; D006854:Hydrocortisone